Home » Stocks » KPTI

Karyopharm Therapeutics, Inc. (KPTI)

Stock Price: $11.09 USD -0.54 (-4.64%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $11.17 +0.08 (0.72%) Mar 8, 7:45 PM
Market Cap 872.48M
Revenue (ttm) 108.09M
Net Income (ttm) -196.27M
Shares Out 72.04M
EPS (ttm) -2.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $11.09
Previous Close $11.63
Change ($) -0.54
Change (%) -4.64%
Day's Open 11.66
Day's Range 11.07 - 11.87
Day's Volume 1,629,058
52-Week Range 10.57 - 25.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

NEWTON, Mass., March 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...

PRNewsWire - 1 week ago

SHANGHAI and HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, devel...

Zacks Investment Research - 3 weeks ago

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.72% and -0.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead fo...

CNBC Television - 1 month ago

Reddit playing a major role in biotech trading action, says Jefferies top health care analyst

Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour...

Other stocks mentioned: MDGL, RCKT
PRNewsWire - 1 month ago

NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its pa...

PRNewsWire - 1 month ago

NEWTON, Mass., Feb. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the C...

PRNewsWire - 1 month ago

NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the Europe...

PRNewsWire - 2 months ago

NEWTON, Mass., Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the C...

PRNewsWire - 2 months ago

NEWTON, Mass., Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michae...

Zacks Investment Research - 2 months ago

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.

PRNewsWire - 2 months ago

SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved t...

Business Wire - 2 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an...

PRNewsWire - 2 months ago

NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...

PRNewsWire - 2 months ago

NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appoi...

PRNewsWire - 2 months ago

NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the N...

PRNewsWire - 3 months ago

NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral pr...

PRNewsWire - 3 months ago

NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over t...

PRNewsWire - 3 months ago

NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it wil...

CNBC - 3 months ago

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Anaplan and Autodesk

Other stocks mentioned: ADSK, PLAN, RPAY
PRNewsWire - 3 months ago

NEWTON, Mass., Nov. 25, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that foll...

PRNewsWire - 3 months ago

NEWTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will pr...

Seeking Alpha - 3 months ago

Xpovio is showing good uptake after about a year on the market. The second line multiple myeloma indication will likely be added next Spring.

Seeking Alpha - 3 months ago

Recent advancements in readouts for Xpovio and Selinexor have yet to be reflected in market pricing, in our view. Karyopharm has had an in line quarter, where Xpovio sales were driven by new p...

PRNewsWire - 3 months ago

NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...

PRNewsWire - 4 months ago

NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twent...

PRNewsWire - 4 months ago

NEWTON, Mass., Nov. 3, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Com...

Seeking Alpha - 4 months ago

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 4 months ago

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 4 months ago

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 0.00% and -0.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...

Benzinga - 4 months ago

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) increased 10.3% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 8.96% over the pas...

PRNewsWire - 4 months ago

NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial r...

PRNewsWire - 4 months ago

NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive t...

Zacks Investment Research - 4 months ago

Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

NEWTON, Mass., Oct. 26, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it wi...

PRNewsWire - 5 months ago

NEWTON, Mass., Oct. 6, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral pr...

PRNewsWire - 5 months ago

NEWTON, Mass., Sept. 14, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

PRNewsWire - 6 months ago

NEWTON, Mass., Sept. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Seeking Alpha - 6 months ago

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: BYSI, GTHX, URGN
Seeking Alpha - 6 months ago

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: BYSI, GTHX, URGN
PRNewsWire - 6 months ago

NEWTON, Mass., Aug. 21, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Seeking Alpha - 7 months ago

Karyopharm Therapeutics, Inc. (KPTI) CEO Michael Kauffman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...

PRNewsWire - 7 months ago

NEWTON, Mass., Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc.

Zacks Investment Research - 7 months ago

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

NEWTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administ...

Seeking Alpha - 7 months ago

Karyopharm has a market cap under $1.5 billion, yet peak sales of Xpovio in just its first 3 indications could easily exceed that figure.

Seeking Alpha - 7 months ago

Karyopharm's XPOVIO Progress And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 7 months ago

NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperati...

GlobeNewsWire - 7 months ago

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the  Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch --

About KPTI

Karyopharm Therapeutics, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company... [Read more...]

Industry
Biotechnology
IPO Date
Nov 6, 2013
CEO
Michael Kauffman
Employees
432
Stock Exchange
NASDAQ
Ticker Symbol
KPTI
Full Company Profile

Financial Performance

In 2020, KPTI's revenue was $108.09 million, an increase of 164.31% compared to the previous year's $40.89 million. Losses were -$196.27 million, -1.66% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is 30.00, which is an increase of 170.51% from the latest price.

Price Target
$30.00
(170.51% upside)
Analyst Consensus: Buy